Incyte (INCY) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued an opinion recommending the approval of Zynyz in combination with carboplatin and paclitaxel for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INCY:
- Intel upgraded, Domino’s downgraded: Wall Street’s top analyst calls
- Wells downgrades Incyte to Equal Weight on lack of catalysts
- Incyte downgraded to Equal Weight from Overweight at Wells Fargo
- Incyte Advances Microneedle Skin Sampling Platform With Completion of Observational Study in Atopic Dermatitis
- Incyte: Transitioning Beyond Jakafi With a Promising but Unproven Late-Stage Pipeline Warrants Hold Rating